**FOI Ref: 6323**

**Category(ies): Clinical - Drugs**

**Subject: Melonoma**

**Date Received: 01/04/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:  * Bevacizumab (Avastin) * Dacarbazine (DTIC) * Trametinib (Mekinist) * Dabrafenib (Tafinlar) * Ipilimumab (Yervoy) * Vemurafenib (Zelboraf) * Nivolumab (Opdivo) * Nivolumab + Ipilimumab (Opdivo + Yervoy) * Pembrolizumab (Keytruda) * Vemurafenib + cobimetinib (Zelboraf + Cotellic) * Dabrafenib + Trametinib (Tafinlar + Mekinist) * Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients * Other active systemic anti-cancer therapy [please state] * Palliative care only | There are no Melanoma diagnoses treated with those drugs or palliative care only either as Primary tumours or Metastatic during this period  SACT - Systemic Anti-Cancer Therapy for Breast cancer patients are delivered by Weston Park; therefore, we are unable to answer this request.  The request would need to go to Sheffield Teaching Hospitals who can be contacted via email at [sth.foi@nhs.net](mailto:sth.foi@nhs.net) |
| 1. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:  * Ipilimumab * Ipilimumab AND Nivolumab * Nivolumab * Pembrolizumab * Dabrafenib AND Trametinib * Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) * Other active systemic anti-cancer therapy * Palliative care only | There are no Melanoma diagnoses treated with those drugs or palliative care only either as Primary tumours or Metastatic during this period  SACT - Systemic Anti-Cancer Therapy for Breast cancer patients are delivered by Weston Park; therefore, we are unable to answer this request.  The request would need to go to Sheffield Teaching Hospitals who can be contacted via email at [sth.foi@nhs.net](mailto:sth.foi@nhs.net) |